Omega-3 fatty acids for depression in adults

Area of Science:

• Neuroscience
• Psychiatry
• Nutritional Science

Background:

• Major depressive disorder (MDD) is a significant global health issue with limited treatment options.
• N-3 polyunsaturated fatty acids (n-3PUFAs), or omega-3 fatty acids, are being investigated as a potential adjunctive therapy for MDD.
• Current evidence on n-3PUFAs for MDD is inconclusive, with observed heterogeneity in study results.

Purpose of the Study:

• To systematically assess the efficacy and safety of n-3PUFAs compared to various comparators for treating MDD in adults.
• To analyze data from randomized controlled trials (RCTs) to determine the impact of n-3PUFAs on depressive symptomology and other relevant outcomes.

Main Methods:

• A comprehensive literature search was conducted across multiple databases and trial registries up to May 2015.
• Included studies were RCTs involving adults with MDD, n-3PUFA intervention, a comparator, and measured depressive symptomology.
• Primary outcomes included depressive symptomology and adverse events; secondary outcomes included remission, response, quality of life, and study completion rates.

Main Results:

• Twenty-six studies (1478 participants) were included; 25 compared n-3PUFAs to placebo, and one compared n-3PUFAs to antidepressants.
• N-3PUFA supplementation showed a small to modest benefit in reducing depressive symptoms versus placebo (SMD -0.32), but with very low-quality evidence and potential bias.
• Adverse events, remission, response rates, and quality of life were similar between n-3PUFA and placebo groups, with wide confidence intervals. The single antidepressant comparison showed no significant difference.

Conclusions:

• High-quality evidence to definitively determine the effects of n-3PUFAs for MDD is currently insufficient.
• The observed small benefit of n-3PUFAs over placebo is likely not clinically meaningful and may be overestimated due to low-quality evidence and potential bias.
• Further research with robust methodology is required to establish the true efficacy and safety profile of n-3PUFAs in MDD treatment.